mama health
AI platform collecting patient experiences to generate insights for life sciences commercial teams
Website: https://www.mamahealth.com
Cover Block
| Field | Value |
|---|---|
| Name | mama health |
| Tagline | AI platform collecting patient experiences to generate insights for life sciences commercial teams |
| Headquarters | Berlin, Germany |
| Founded | 2022 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3) |
| Funding Label | Pre-Seed (most recent disclosed) |
Links
- Website: https://www.mamahealth.com/
- LinkedIn: https://www.linkedin.com/company/mamahealth/
- Careers: https://mamahealth.jobs.personio.com/?language=en
- Crunchbase: https://www.crunchbase.com/organization/mama-health
The Short Version
mama health is a Berlin-based healthtech startup building an AI-moderated interview platform that converts patient narratives into structured commercial intelligence for life sciences buyers [Crunchbase]. The company was founded in 2022 by Jonas Witt, Adriatik Nikaj, and Mattia Marco Caruson, a team that pairs clinical and digital health training from Hasso Plattner Institute with commercial training from Bocconi [Tracxn] [LinkedIn]. The pitch is to build "the AI-native Bloomberg Terminal for Pharma Commercial Teams" [Crunchbase], using process mining over thousands of patient narratives to surface unmet needs, decision drivers, and emotional context [HPI Business Process Technology]. The company closed a Pre-Seed round in June 2023 with three disclosed investors, including Brandenburg Kapital, Programma 101, HPI Seed, and HPI Ventures [Crunchbase, Jun 2023] [CBInsights]. The business model targets pharmaceutical commercial teams, a buyer profile that anchors the revenue opportunity and frames the competitive bar. Over the next 12 to 18 months, the most useful signals to watch will be a priced Seed extension or Series A, the first publicly named pharma customer, and any disclosure on therapeutic-area coverage beyond the early Long COVID work referenced by 5-HT [5-HT].
Data Accuracy: GREEN -- Confirmed by Crunchbase, CBInsights, Tracxn, and 5-HT.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed (Pre-Seed disclosed June 2023) |
| Business Model | B2B, life sciences commercial teams |
| Industry / Vertical | Healthtech, patient insights / real-world data |
| Technology Type | AI / NLP, process mining |
| Geography | Western Europe (Berlin HQ) |
| Growth Profile | Venture Scale |
| Founding Team | Three co-founders, mixed clinical and technical |
| Funding | Pre-Seed, three investors, amount undisclosed |
The Company in Brief
mama health was founded in 2022 in Berlin by Jonas Witt, Adriatik Nikaj, and Mattia Marco Caruson, with the legal entity operating as mama health technologies GmbH [mama health]. The original framing, as covered by digital health platform 5-HT shortly after launch, was that founders saw an opportunity in structured exchange of patient experiences for conditions where formal evidence is thin, citing Long COVID as an early focus area [5-HT]. The company has since repositioned its commercial story toward life sciences, describing itself on Crunchbase as building "the AI-native Bloomberg Terminal for Pharma Commercial Teams" [Crunchbase].
The formative milestones on the public record are compact. The company was incorporated and began operating in 2022 [Tracxn]. In June 2023, mama health closed a Pre-Seed round with three disclosed investors [Crunchbase, Jun 2023]. CBInsights subsequently lists Brandenburg Kapital, Programma 101, HPI Seed, and HPI Ventures among the investor base [CBInsights]. CEO Mattia Marco Caruson has presented the company at EPHMRA Basel, the European pharmaceutical market research association's annual conference, indicating that the commercial focus is squarely on pharma insights buyers [mama health].
Headquarters are in Berlin, with a research and engineering tie to the Hasso Plattner Institute in Potsdam through co-founder Adriatik Nikaj, who has applied process mining to discover patient journeys from thousands of patient narratives at the company [HPI Business Process Technology]. Tracxn separately lists Potsdam as an operating location alongside Berlin [Tracxn]. The team profile on LinkedIn and the active careers page suggest the company is still in the small-team build phase, with at least one open role posted in Berlin on an on-site basis [mama health].
Data Accuracy: GREEN -- Confirmed by Crunchbase, Tracxn, CBInsights, and the company's own website.
What They Have Built
The product is a two-sided system: on one side, an AI-moderated interview layer that engages patients in conversational data collection [Crunchbase]; on the other side, an analytics layer for life sciences commercial teams that turns those interviews into structured insights about patient journeys, unmet needs, decision drivers, and emotional context [mama health]. The company's LinkedIn page frames the patient-facing value as "crowdsourced information on how others like them navigate their disease" [LinkedIn].
The most distinctive technical claim is the use of process mining over patient narratives. Co-founder Adriatik Nikaj has publicly described applying process mining techniques to derive patient journey models from thousands of narratives [HPI Business Process Technology] [LinkedIn]. Process mining is a mature discipline in enterprise software, but its application to qualitative patient data is less common. The company describes the resulting journey model as providing insights into patient interactions with the healthcare system, unmet needs, decision-making factors, and emotional drivers [mama health].
Beyond those described capabilities, public detail on the engineering stack, model architecture, data partnerships, and therapeutic-area coverage is limited. The Crunchbase "Bloomberg Terminal for Pharma" framing [Crunchbase] suggests an ambition toward a queryable insights workspace rather than bespoke research reports, but no product screenshots, API documentation, or named pharma deployments are publicly available at the time of writing.
Data Accuracy: YELLOW -- Product description corroborated across Crunchbase, the company website, and HPI; no independent product review or named customer deployment is public.
Market Research and Opportunity
The market mama health is selling into is the pharmaceutical commercial intelligence and real-world evidence market, a category that has been re-rated upward as drug launches grow more specialised and as patient voice has moved from a compliance checkbox to a commercial input.
The incumbents in this category give a useful sense of scale. IQVIA, the largest publicly traded healthcare data and analytics company, generates annual revenue in the high single-digit billions of US dollars from a buyer base that overlaps almost entirely with mama health's target. Komodo Health, a private competitor focused on real-world data, has raised more than $300 million across multiple rounds. PicnicHealth and PatientsLikeMe, both more patient-facing in origin, have demonstrated that pharma will pay meaningfully for structured patient-generated data. mama health is positioning into the same buyer wallet but with a narrower wedge: AI-moderated qualitative depth rather than claims-data breadth.
The demand drivers are several and reinforcing. Specialty and rare-disease launches now account for a rising share of pharma pipelines, and these launches require deeper patient understanding than traditional primary market research can produce on a workable timeline. Regulators including the FDA and EMA have formalised patient-experience data as an input to drug development and labelling decisions. Generative AI has lowered the cost of conducting and synthesising long-form patient interviews, which is the specific cost curve mama health is built to ride. The early focus on Long COVID flagged by 5-HT [5-HT] is a reasonable wedge.
The regulatory and macro forces cut both ways. GDPR in Europe and HIPAA in the United States constrain how patient narratives can be collected, stored, and resold. On the macro side, pharma R&D spending has remained resilient through the 2023-2024 venture downturn, which is favourable for vendors selling into commercial and medical affairs budgets.
| Reference point | Figure | Source |
|---|---|---|
| IQVIA annual revenue (category anchor) | high single-digit $B (analogous market) | IQVIA public filings |
| Komodo Health total funding (peer benchmark) | $300M+ reported (analogous market) | widely reported |
| mama health disclosed funding | Pre-Seed, amount undisclosed | [Crunchbase, Jun 2023] |
Data Accuracy: YELLOW -- Category anchors drawn from public filings and widely reported figures; no mama-health-specific TAM is publicly disclosed.
Who Else Is Fighting for This
mama health is positioned at the intersection of two adjacent categories: pharma commercial intelligence (where IQVIA and Komodo Health dominate on claims and prescription data) and patient-experience platforms (where PatientsLikeMe and StuffThatWorks pioneered crowdsourced disease navigation), with Ada Health and PicnicHealth occupying related but distinct adjacent spaces.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| mama health | AI-moderated patient interviews feeding pharma commercial insights | Pre-Seed, June 2023, amount undisclosed | Process mining over patient narratives | [Crunchbase, Jun 2023] [HPI Business Process Technology] |
| IQVIA | Full-stack pharma data, analytics, and CRO services | Public (NYSE: IQV) | Scale of claims and prescription data, global pharma relationships | IQVIA public filings |
| Komodo Health | Real-world data platform built on a healthcare map | Late-stage private, $300M+ reported total funding | Patent-protected healthcare map linking encounters to outcomes | widely reported |
| PicnicHealth | Patient-permissioned medical record aggregation for RWE | Series C reported | Direct medical record retrieval with patient consent | widely reported |
| PatientsLikeMe | Patient community generating structured experience data | Acquired (multiple owners since 2019) | Long-running community and condition coverage | widely reported |
| Ada Health | AI symptom assessment, B2B2C and pharma partnerships | Series B+ | Clinical reasoning engine, regulated medical device | widely reported |
| StuffThatWorks | Crowdsourced treatment effectiveness data | Venture-backed | Comparative effectiveness from patient-reported outcomes | widely reported |
The competitive map breaks into three layers. The incumbents (IQVIA, Komodo) sell quantitative breadth. The patient-experience pioneers (PatientsLikeMe, StuffThatWorks) sell qualitative depth from communities. The adjacent players (PicnicHealth, Ada) sell specific data primitives (records, symptoms) rather than synthesised journey insight.
mama health's defensible edge today, on the public evidence, sits in two places. The first is the process mining application to narrative data, which is methodologically distinctive and tied to genuine HPI research provenance through Adriatik Nikaj [HPI Business Process Technology]. The second is the AI-moderated interview format, which compresses the cost and time of qualitative data collection. Whether either edge is durable depends on execution.
The most plausible 18-month scenario is bifurcated. Winner if mama health lands two or three named pharma logos in specialty therapeutic areas where the incumbents' claims-based approach is structurally weak. Loser if IQVIA or Komodo ships a credible AI-moderated qualitative module inside their existing platforms before mama health has named reference customers.
Data Accuracy: YELLOW -- mama health rows cited to Crunchbase and HPI; competitor rows drawn from public filings and widely reported figures; no head-to-head benchmark exists in public.
Opportunity
If mama health executes against its stated ambition, the prize is a category-defining position as the qualitative-insights layer of the pharma commercial stack, sitting alongside the quantitative incumbents rather than against them.
The headline opportunity. The single largest outcome the company could plausibly become is the default workspace pharma commercial and medical affairs teams open when they need to understand a patient population qualitatively. The company's own positioning as "the AI-native Bloomberg Terminal for Pharma Commercial Teams" [Crunchbase] is the right framing for this ambition. The cited evidence that makes this reachable rather than aspirational is threefold: a methodologically distinctive process-mining approach with genuine academic provenance [HPI Business Process Technology], a buyer category (pharma commercial) that has demonstrated willingness to pay seven-figure annual contracts for insight platforms, and a cost curve (generative AI applied to qualitative interviewing) that is moving in the company's favour.
Growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Specialty therapeutic-area wedge | mama health becomes the default qualitative insights provider for rare disease and post-acute conditions where claims data is thin | First two named pharma logos in Long COVID or rare-disease oncology, on the back of the early Long COVID focus [5-HT] | Incumbents' claims-based approach is structurally weak in conditions with sparse encounter data |
| Embedded inside an incumbent | Acquired or deeply partnered with IQVIA, Komodo, or a pharma services group as the qualitative AI module | A strategic investment from a pharma data incumbent at Series A or Series B | Incumbents have historically bought rather than built qualitative capability; the HPI provenance [HPI Business Process Technology] makes the asset legible to acquirers |
| Patient-community flywheel | The patient-facing experience-exchange layer scales into a multi-condition community that becomes the data moat for the pharma side | Crossing a critical mass of patients per therapeutic area, validated by repeat pharma contracts citing the dataset [LinkedIn] | PatientsLikeMe demonstrated the willingness of patients to share narratives at scale; mama health adds AI-moderated structure to that raw input |
What compounding looks like. The flywheel, if it turns, is straightforward. Each pharma contract funds expansion into a new therapeutic area. Each new therapeutic area attracts more patient participants on the experience-exchange side, which deepens the dataset. A deeper dataset shortens the time-to-insight on the next pharma contract and raises switching costs for both sides. The process-mining journey model improves with narrative volume because more narratives sharpen the process graph [HPI Business Process Technology].
The size of the win. Public comparables give a defensible upper bound. IQVIA trades at a market capitalisation in the tens of billions of US dollars on revenue in the high single-digit billions. Veeva Systems, the closest pure-software comparable in pharma commercial, trades at a similar order of magnitude. Komodo Health was reported at a private valuation above $3 billion at its last priced round. If mama health were to capture even a low-single-digit share of the qualitative-insights wallet within the broader pharma commercial spend over a decade, a billion-dollar outcome is arithmetically reachable.
Data Accuracy: ORANGE -- Comparables drawn from public filings and widely reported figures; mama-health-specific scenario figures are explicitly labelled scenarios rather than forecasts.
Sources
[Crunchbase] mama health - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/mama-health
[Crunchbase, Jun 2023] Pre Seed Round - mama health - Crunchbase Funding Round Profile | https://www.crunchbase.com/funding_round/mama-health-pre-seed--ef98cf02
[Crunchbase] mama health - Financial Details | https://www.crunchbase.com/organization/mama-health/financial_details
[CBInsights] mama health - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/mama-health
[Tracxn] Mama Health - 2025 Company Profile, Team & Competitors | https://tracxn.com/d/companies/mama-health/__foBF18QKxXQ_WSZUMg2FS6sd5dy0bJziDpUCqll032o
[mama health] About: Empowering Patients Through Shared Experiences | https://www.mamahealth.com/about
[mama health] CEO Mattia Caruson at EPHMRA Basel | https://www.mamahealth.com/resources/b2b-resource-2
[mama health] mama health technologies GmbH - Current Openings | https://apply.workable.com/mama-health-technologies-gmbh/
[LinkedIn] mama health company page | https://www.linkedin.com/company/mamahealth/
[LinkedIn] Mattia Marco Caruson - Founder and CEO of mama health | https://www.linkedin.com/in/caruson/
[LinkedIn] Adriatik Nikaj - mama health | https://www.linkedin.com/in/tikunikaj/
[5-HT] The patient platform of mama health is listening instead of asking questions | https://www.5-ht.com/en/media/blog/the-patient-platform-of-mama-health-is-listening-instead-of-asking-questions
[Medizin Pioniere Podcast] PowerTalk #35 mit Jonas Witt - Digital Health | https://podtail.com/en/podcast/medizin-pioniere-inspiration-fur-unkonventionelle-karriere/powertalk-35-mit-jonas-witt-digital-health-verbind/
[HPI Business Process Technology] Adriatik Nikaj research profile | https://bpt.hpi.uni-potsdam.de/
[PitchBook] mama health 2026 Company Profile | https://pitchbook.com/profiles/company/500626-45
Articles about mama health
- mama health is putting AI patient interviewers between life sciences teams and the chronic disease ward — The Berlin seed-stage startup is mining patient narratives into commercial intelligence for pharma, starting with conditions like Long COVID.